ProStrakan is unique in that it comprises all the elements necessary for a sustainable pharmaceutical business - and is demonstrably successful in each area.
Institutional investors
Leading Institutional investors in ProStrakan:
- Warburg Pincus International Partners LP 17.93%
- Aventis Pharma SA 12.70%
- Warburg Pincus Private Equity VIII LP 10.71%
- LMS Capital (Bermuda) Limited 7.64%
- Warburg Pincus Equity Partners LP 6.37%
- BNY/OCS/Nominees Limited (3i plc) 6.27%
- Morstan Nominees Ltd 4.91%
Warburg Pincus through various entities collectively holds 36.46%
Directors, employees and non-institutional shareholders hold 15% of the company.
